HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC
Status:
Recruiting
Trial end date:
2023-11-10
Target enrollment:
Participant gender:
Summary
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC)
Combined With Sintilimab and Bevacizumab Biosimilar in the First-Line Treatment of Patients
With Advanced Unresectable Hepatocellular Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital